Wilson Frank Anders 4

Accession 0001127602-24-017731

CIK 0001520262other

View on SEC.gov Company Profile

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 5:03 PM ET

Size

31.8 KB

Accession

0001127602-24-017731

Insider Transaction Report

Form 4

Period: 2024-05-31

Alkermes plc.ALKS

Wilson Frank Anders

Director

Transactions

Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$20.81/sh+1,236$25,721→ 63,036 total
Exercise: $20.81Exp: 2029-12-04→ Ordinary Shares (1,236 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$24.24/sh+313$7,587→ 15,990 total
Exercise: $24.24Exp: 2031-06-14→ Ordinary Shares (313 underlying)
Other
Restricted Stock Unit Award
2023-11-17+119→ 6,104 total
From: 2024-06-29→ Ordinary Shares (119 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.86/sh+231$7,129→ 11,785 total
Exercise: $30.86Exp: 2032-07-07→ Ordinary Shares (231 underlying)
Award
Non Qualified Stock Option (Right to Buy)
2024-05-31+17,492→ 17,492 total
Exercise: $23.40From: 2025-05-31Exp: 2034-05-31→ Ordinary Shares (17,492 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$16.52/sh+256$4,229→ 13,079 total
Exercise: $16.52Exp: 2030-05-20→ Ordinary Shares (256 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.72/sh+254$7,803→ 12,986 total
Exercise: $30.72From: 2024-06-29Exp: 2033-06-29→ Ordinary Shares (254 underlying)
Award
Restricted Stock Unit Award
2024-05-31+8,013→ 8,013 total
From: 2025-05-31→ Ordinary Shares (8,013 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$20.81/sh+224$4,661→ 11,424 total
Exercise: $20.81Exp: 2029-12-04→ Ordinary Shares (224 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$18.45/sh+230$4,244→ 11,739 total
Exercise: $18.45Exp: 2030-12-02→ Ordinary Shares (230 underlying)

Footnotes (7)

[F1]Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
[F2]These options are fully vested in accordance with their terms.
[F3]Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
[F4]Each restricted stock unit represents a contingent right to receive one ordinary share.
[F5]Shares subject to the restricted stock unit award vest in full on 6/29/2024.
[F6]Shares subject to the restricted stock unit award vest in full on 5/31/2025.
[F7]Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

Documents

2 files

Issuer

Alkermes plc.

CIK 0001520262

→

Entity typeother

Related Parties

filerCIK 0001462948

Filing Metadata

Form type: 4
Filed: Jun 3, 8:00 PM ET
Accepted: Jun 4, 5:03 PM ET
Size: 31.8 KB

View on SEC.gov